Clinical Trial Activities
- Home
- Clinical Trials
Clinical Trials
COVID-19 / Acute Respiratory Distress Syndrome (ARDS)
FDA granted numerous Emergency INDs to treat Covid-19 using our mesenchymal stem cells, which showed remarkable safety and efficacy even in advanced COVID Pneumonia and ARDS.
FDA approved a Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients with Severe Lung Injury due to COVID-19 or Other Infectious Pathogens.
DCGI (India FDA) approved a similar clinical trial in India to investigate the use of mesenchymal stem cells for severe lung injury from COVID-19 or other pneumonia.
Clinical Trial Activities
COVID-19 / Acute Respiratory Distress Syndrome (ARDS)
The respiratory ailment known as coronavirus disease 2019 (COVID-19) is contagious. This is a brand-new coronavirus that has never been observed in humans before. It causes a variety of symptoms, with some patients reporting trouble breathing or shortness of breath.
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients with Severe Lung Injury due to COVID-19 or Other Infectious Pathogens is a multisite clinical trial that Sanostem is starting with FDA approval to investigate the use of mesenchymal stem cells for severe lung injury from COVID-19 or other pneumonia.
